clinical trial · NCT06862869
Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
Hoffmann-La Roche·—·recruiting·n = 800
Carcinoma, Non-Small-Cell LungAlectinib
brief summary
This study is a multicenter, prospective, cohort study designed to evaluate the clinical outcomes and characteristics of resected stage II-IIIB anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) adult patients treated with Alectinib as adjuvant therapy in China.
started
Apr 30, 2025
primary completion
Oct 30, 2028
completion
Apr 30, 2029
last updated
Apr 6, 2026
official title
Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy in China: A Multicenter, Prospective Cohort Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol